Drug intelligence / Profile preview

insulin lispro + insulin ultralente + regular insulin

Development stage: Unknown
Lead developer: Eli Lilly
Modality: Recombinant Proteins and Enzymes
Administration: Subcutaneous

Overview

A combination of three insulin types with different onset and duration profiles. Insulin lispro is a rapid-acting insulin analog with faster absorption and shorter duration than regular insulin. Regular insulin is a short-acting insulin. Insulin ultralente is a long-acting insulin with minimal peak effect and duration of up to 36 hours. This combination is not a standard pre-mixed formulation but represents individual insulins that might be mixed for specific patient needs in diabetes management.

Targets

INSR (Insulin receptor)

Beyond the preview

Go deeper on insulin lispro + insulin ultralente + regular insulin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on insulin lispro + insulin ultralente + regular insulin.

Explore the full profile